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Abstract This review summarizes the available
evidence-based data that form the basis for therapeutic
intervention and covers the current status of glucocorti-
coid-induced osteoporosis (GIOP) management, regulatory
requirements, and risk-assessment options. Glucocorticoids
are known to cause bone loss and fractures, yet many
patients receiving or initiating glucocorticoid therapy are
not appropriately evaluated and treated. An European
Society for Clinical and Economic Aspects of Osteoporosis
and Osteoarthritis workshop was convened to discuss
GIOP management and to provide a report by a panel of
experts. An expert panel reviewed the available studies that
discussed approved therapeutic agents, focusing on ran-
domized and controlled clinical trials reporting on bone
mineral density and/or fracture risk of at least 48 weeks’
duration. There is no evidence that GIOP and postmeno-
pausal osteoporosis respond differently to treatments. The
FRAX algorithm can be adjusted according to glucocorti-
coid dose. Available antiosteoporotic therapies such as
bisphosphonates and teriparatide are efficacious in GIOP
management. Several other agents approved for the treat-
ment of postmenopausal osteoporosis may become avail-
able for GIOP. It is advised to stop antiosteoporotic
treatment after glucocorticoid cessation, unless the patient
remains at increased risk of fracture. Calcium and vitamin
D supplementation as an osteoporosis-prevention measure
is less effective than specific antiosteoporotic treatment.
Fracture end-point studies and additional studies investi-
gating specific subpopulations (pediatric, premenopausal,
or elderly patients) would strengthen the evidence base and
facilitate the development of intervention thresholds and
treatment guidelines.
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Glucocorticoids are widely used to suppress inflammation
and to treat various immune-mediated diseases, such as
rheumatic diseases (rheumatoid arthritis, polymyalgia
rheumatica, systemic lupus erythematosus, vasculitis), lung
diseases, inflammatory bowel disease, chronic liver dis-
ease, and skin diseases, or in organ transplant recipients.
Glucocorticoid use is associated with deleterious effects on
bone (Fig. 1), leading to glucocorticoid-induced osteopo-
rosis (GIOP), a common cause of secondary osteoporosis.
Long-term glucocorticoid therapy causes osteoporotic
fractures in *30–50 % of treated adult patients [reviewed
in 1].
A particular characteristic of GIOP is early rapid bone
loss [2]. Early intervention with bone protective therapy is
therefore important in individuals at increased risk of
fracture [3]. Compared with postmenopausal osteoporosis,
fewer studies have investigated treatment efficacy in GIOP
patients [4], despite the fact that *1.4–1.7 % of women in
the United Kingdom above the age of 55 receive gluco-
corticoid therapy [5, 6]. Of note, glucocorticoid use varies
markedly in different countries. The global longitudinal
study of osteoporosis in women (GLOW) observational
study reported higher use of glucocorticoids in women
above the age of 55 years (2.7–4.6 %), but sampling was
weighted toward older and less healthy subjects [7].
Although glucocorticoids are known to cause bone loss
and fractures, many patients receiving or starting long-term
glucocorticoid therapy are not appropriately evaluated
and treated, in terms of bone health and fracture
prevention [8].
This review summarizes the available evidence-based
data that form the basis for therapeutic intervention and
cover the current status of GIOP management, regulatory
requirements, and options for risk assessment.
Methods
A workshop was convened to identify areas of consensus
among a panel of experts (the authors), with the objective of
discussing the available data for the evaluation and manage-
ment of GIOP. The studies included in this position paper
reflect those discussed by the panel during the workshop.
The studies discussed approved therapeutic agents,
focusing on randomized controlled clinical trials (RCTs) of
human subjects reported in English. The emphasis was on
studies with information on bone mineral density (BMD)
and/or fracture, with a minimum duration of 48 weeks.
Relevant meta-analyses were also described. In cases
where RCT data were not available as supportive evidence,
qualitative literature reviews and expert-identified articles
were used to summarize the existing evidence.
Epidemiology
Epidemiological data on GIOP mostly relate to oral glu-
cocorticoid therapy given continuously for 3–6 months or
longer. In 2000, *0.9 % of the total adult population in the
United Kingdom used oral glucocorticoids (2.5–7.5 mg
prednisolone or equivalent) at any one time. Of these, an
estimated 22 % took higher doses long term ([6 months)
[6]. A pharmacies database study of glucocorticoid pre-
scriptions in Iceland collected over a 2-year period,
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combined with information obtained from medical records,
estimated that 26 % of patients on long-term glucocorti-
coid therapy ([6 months) develop osteoporosis [9].
Fracture rates increase with age regardless of gluco-
corticoid use in both men and women, but there is an
additional dose-dependent increase in risk for people tak-
ing higher doses of oral glucocorticoids [10, 11]. Daily
doses of C5 mg prednisolone have been shown to increase
fracture risk by about 20 %, rising to 60 % in individuals
on C20 mg/day [2, 12]. In a meta-analysis of *42,000
subjects from seven cohort studies across different coun-
tries, current and past glucocorticoid use was an important
predictor of fracture risk, independent of prior fracture and
BMD. Relative risk of any fracture ranged from 1.98 at the
age of 50 years to 1.66 at the age of 85 years. Relative risk
ranged 2.63–1.71 and 2.48–4.42 for osteoporotic and hip
fractures, respectively [13].
Cumulative glucocorticoid dose correlates strongly with
loss of BMD [2]. A correlation has also been established
between daily dose and fracture risk, which increases
rapidly (within 3–6 months of initiating oral glucocorticoid
therapy) and independently of underlying disease, age, and
gender [14]. The underlying disease being treated often
contributes to loss of bone mass and increased fracture risk
[15]. Factors such as general health status, age, sex, body
mass index (BMI), fracture history (personal and family),
diet, exercise, smoking, alcohol consumption, and meno-
pausal status must also be considered when evaluating
fracture risk [12].
Nature of Glucocorticoid Therapy
Glucocorticoid doses and treatment schedules vary con-
siderably among patients, complicating the quantification
of fracture risk. Daily prednisolone doses as low as 2.5 mg
have been associated with increased fracture risk [12].
However, the effects on bone of low-dose oral glucocor-
ticoids, as well as of inhaled glucocorticoids and inter-
mittent dosing, are not yet fully established [16].
An increased risk of vertebral fracture has been reported
in patients on inhaled glucocorticoid therapy, although this
effect was less pronounced than with systemic glucocorti-
coid therapy [16]. Inhaled low-dose glucocorticoids are not
associated with increased fracture risk [17], whereas
inhaled beclomethasone above 800 lg/day was associated
with a small increase in fracture risk [18]. The metabolic
impact of inhaled corticosteroids is reviewed elsewhere
[19]. An increased risk of fracture has been reported in
children on inhaled glucocorticoid therapy, but after
adjusting for asthma severity, the risk disappeared. Thus, it
is likely that the increase in fracture risk was related to the
underlying disease as well [20].
Few studies have documented the effect of intermittent
(pulse) therapy on bone metabolism. Early studies con-
cluded that bone metabolism was not seriously affected
during glucocorticoid pulse therapy but that hypercalciuria
was consistently reported [21–23]. Although a significant
increase is initially seen in serum calcium, parathyroid
hormone (PTH), and 1,25-dihydroxyvitamin D, these
Fig. 1 Effects of
glucocorticoids on bone
metabolism (adapted from
[29, 35, 121]). Dkk-1 dickkopf-
1, OPG osteoprotegerin,
RANKL receptor activator
of nuclear factor jB ligand,
BMP bone morphogenetic
protein, GSK3b glycogen
synthase kinase 3b, PPAR
peroxisome proliferator–
activated receptor,
Runx2 runt-related protein 2,
AP-1 activator protein 1
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values typically return to baseline levels in subsequent
pulses. Rather than an actual increase in PTH levels, a
greater sensitivity of bone cells to PTH induced by glu-
cocorticoids has been advocated [24]. Contrary to expec-
tations, the use of long-term, intermittent, high-dose
glucocorticoids in children, after adjusting for BMI, has
been linked with an increase in whole-body bone mineral
content and maintenance of the bone mineral content of
the lumbar spine [25]. Typically, however, there is an
increased fracture risk associated with intermittent gluco-
corticoid use, with higher doses and more frequent use
leading to greater risk [17]. Oral pulse therapy increases
vertebral fracture risk similarly to inhaled glucocorticoids,
but these patients are less likely to fracture than those on
continuous therapy [26, 27].
Although withdrawal of glucocorticoids leads to a
reduction in fracture risk, it is not clear whether the risk
returns to baseline values [4, 27, 28]. In one case–con-
trolled study, it took [1 year for fracture risk to return to
the general population level [29]. There is some evidence
that BMD loss is partially reversible upon cessation of
glucocorticoid therapy [4, 10, 30]. This raises the question
of when to discontinue antiosteoporotic treatment after
cessation of glucocorticoid use as there is no current
consensus.
Pathophysiology
Reduced bone formation is the key process in GIOP and
probably the main difference between GIOP and post-
menopausal osteoporosis. Even at low doses, glucocorti-
coids have been shown to rapidly and significantly suppress
several indices of osteoblast activity, including serum
propeptide of type I N-terminal procollagen (P1NP), pro-
peptide of type I C-terminal procollagen (P1CP), and
osteocalcin [31]. Glucocorticoid-induced apoptosis of
osteoblasts and osteocytes has long been recognized in the
pathophysiology of GIOP [1, 32, 33], but it is only in the
past few years that our understanding of the molecular
mechanisms involved has extended to a more in-depth
process (Fig. 1).
It has been suggested that osteocyte–canalicular network
interruption, could trigger apoptosis in the immediately
surrounding cells and activate bone remodeling [34].
Recent studies have identified activation of caspase-3 as an
important trigger for osteoblast and osteocyte apoptosis.
Osteoblast loss has also been linked with activation of
glycogen synthase kinase 3b (GSK3b), a serine/threonine-
specific protein kinase involved in the Wnt signaling
pathway [35].
In bone metabolism, the Wnt signaling pathway plays an
important role in osteoblastogenesis. This pathway is
negatively regulated by dickkopf-1 (Dkk-1) and sclerostin.
Glucocorticoids upregulate expression of these inhibitors
[36, 37], thereby suppressing the binding of Wnt to low-
density lipoprotein receptor–related proteins 5 and 6
(LPR5/-6). This leads to a reduced ability to stabilize
b-catenin and to the inhibition of bone formation by
blocking the transcription of target genes [35].
Glucocorticoids also stimulate osteoblast precursor cells
in bone marrow (bone marrow stromal cells) to differen-
tiate toward adipogenesis instead of osteoblastogenesis.
High-dose glucocorticoids may initiate this preferential
shift through the repression of activator protein 1 (AP-1),
which is further implicated in the regulation of genomic
anti-inflammatory activity [35]. Other important processes
include upregulation of expression of peroxisome prolif-
erator–activated receptor c2 (PPARc2) and repression of
runt-related protein 2 (Runx2) [35]. In contrast to osteo-
blastogenesis, osteoclastogenesis is rather promoted by
glucocorticoid use. Osteoclast apoptosis is suppressed
during glucocorticoid therapy, through both inhibition of
osteoprotegerin (OPG) and increased expression of recep-
tor activator for nuclear factor-jB ligand (RANKL). The
Wnt signaling pathway is a candidate mechanism for glu-
cocorticoid-mediated suppression of OPG. Direct effects of
glucocorticoids on osteoclasts have been shown in vitro to
result in a reduced capacity for bone resorption [35].
In addition to their direct effects on osteoblasts, osteo-
clasts, and osteocytes, glucocorticoids exert indirect effects
on bone by reducing intestinal calcium absorption and
increasing renal calcium clearance and by affecting gona-
dal hormones and the neuromuscular system (as seen by an
increased propensity for falls in glucocorticoid-treated
patients) [1]. Overall, these effects on bone metabolism
contribute to early and rapid bone loss and increased
fracture risk [1, 29, 38, 39]. Furthermore, continuous
exposure to glucocorticoids has been shown to increase
expression of genes that inhibit bone mineralization (Dmp-
1, Phex). Glucocorticoid transrepression of two important
matrix proteins, osteocalcin and type 1 collagen, may have
an additional effect on bone mineralization [35].
Comparisons of the pathophysiology of GIOP and
postmenopausal osteoporosis may have some parallels with
comparisons of osteoporosis in men vs. women. Although
the pathophysiology of osteoporosis differs between the
sexes, there are similarities in the relationship of BMD to
fracture and treatment response. In the context of GIOP,
however, additional factors, such as age and comorbidity
profiles and the fact that glucocorticoids have a negative
effect on muscle strength, may obscure such parallels.
Patients with GIOP fracture at a lower BMD value than
those with postmenopausal osteoporosis [2]. A potential
biological basis for the focus on older age as an indepen-
dent risk factor was highlighted in studies indicating that
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the effects of glucocorticoids on bone are dependent on
autocrine actions of 11b-hydroxysteroid dehydrogenase
type 1 (11b-HSD1), the expression of which facilitates
local synthesis of active glucocorticoids in osteoblasts,
affecting their proliferation and differentiation. Age-spe-
cific variation in osteoblastic 11b-HSD1 was characterized
using primary cultures of human osteoblasts. 11b-HSD1
reductase activity was detected in all osteoblast cultures,
which correlated positively with age. Moreover, gluco-
corticoid treatment caused a time- and dose-dependent
increase in 11b-HSD1 activity compared with controls.
Thus, activation of glucocorticoids at an autocrine level
within bone may have a role in the age-related decrease in
bone formation and increased GIOP risk [40].
Intervention Thresholds
In GIOP, the terms ‘‘prevention’’ and ‘‘treatment’’ distin-
guish between the initiation of antiosteoporosis interven-
tion at the start of glucocorticoid therapy and after
C3 months of glucocorticoid therapy. Ideally, however, the
timing of antiosteoporotic intervention in GIOP would be
based on absolute fracture risk [41]. The World Health
Organization (WHO) developed the FRAX computer-
based fracture risk-assessment tool (http://www.shef.
ac.uk/FRAX) to calculate 10-year fracture probability
from clinical risk factors with or without BMD testing [42,
43]. This risk-assessment tool provides estimates of frac-
ture probability in individuals receiving glucocorticoid
doses (2.5–7.5 mg/day), whereas the algorithm can be
adjusted according to glucocorticoid dose defined in terms
of prednisolone-equivalent doses [44]. For low-dose
exposure (\2.5 mg/day prednisolone equivalent) the
probability of a major fracture may need revising down-
ward, depending on age, whereas with high doses
([7.5 mg/day) probabilities can be revised upward
[44, 45].
Various guidelines for GIOP stress the importance of
initiating antiosteoporosis prophylaxis in patients receiving
chronic glucocorticoid therapy [46, 47]. The most recent
(2010) recommendations from the American College of
Rheumatology (ACR) are stratified by glucocorticoid dose
and fracture risk based on FRAX calculations. They rec-
ommend that low- and medium-risk patients (FRAX \10
and 10–20 % probability of a major fracture, respectively)
should be treated if their glucocorticoid dose is C7.5 mg/
day. High-risk patients (FRAX[20 %) should be treated if
they receive glucocorticoids at any dose for[1 month or if
they are on C5 mg/day prednisolone equivalent even for
\1 month [46]. The 10 % threshold is lower than the
generally accepted 20 % threshold for postmenopausal
osteoporosis in use in North America.
Further recommendations from the ACR include
avoiding routine osteoporosis prophylaxis in young women
of childbearing potential who are due to receive gluco-
corticoids for \3 months. In premenopausal women who
will receive glucocorticoids for C3 months, it is assumed
that the fracture risk is high enough to recommend treat-
ment with alendronate, risedronate, zoledronic acid, or
teriparatide to prevent GIOP [46].
A joint Guideline Working Group of the International
Osteoporosis Foundation (IOF) and European Calcified
Tissue Society (ECTS) recently published a framework for
the development of national guidelines for the management
of GIOP [47]. The IOF–ECTS recommends that, in post-
menopausal women and men aged C50 years exposed to
C3 months of oral glucocorticoids, a decision should be
made on whether to consider treatment directly or to assess
risk with adjusted FRAX (with or without BMD testing).
This decision should be based on history of fracture, age
(C70 years), and glucocorticoid dose (C7.5 mg/day);
intervention thresholds will depend on the country. In
premenopausal women and men aged \50 years exposed
to C3 months of oral glucocorticoids, treatment should be
considered in patients with prior fracture. Treatment deci-
sions in individuals with no prior fracture should be based
on clinical judgment. In addition, it is recommended that
all individuals receiving glucocorticoid therapy should be
counseled as to the risks of treatment. General measures
(e.g., good nutrition and regular weight-bearing exercise)
should be taken, and patients should be monitored as
appropriate (Appendix) [47].
Regulatory Requirements
Current European guidelines for the evaluation of new
medicinal products in the treatment of primary osteoporo-
sis do not include any requirements for GIOP [48, 49].
However, work is in progress to provide guidelines for this
group of patients, including pediatric subjects. The simi-
larities with respect to the pathophysiology of bone loss
between GIOP and postmenopausal osteoporosis, including
increased bone resorption (at least initially in GIOP) and
reduced bone formation, form the basis of the claim for a
BMD end point in GIOP as being sufficient (reviewed in
[41]).
In line with WHO guidelines [50], patients starting
glucocorticoid therapy and/or those already on glucocorti-
coid therapy may be included in phase III clinical trials.
Stratification by duration of glucocorticoid use may be
recommended. Phase III trials in GIOP should aim to
demonstrate a minimum of 2-year superior antifracture
efficacy (vertebral and/or nonvertebral fractures) vs. pla-
cebo in a randomized, double-blind study. For the
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treatment of GIOP in postmenopausal women, bridging
studies may be performed with drugs (same formulation,
dose, and route of administration) already approved in this
patient population, provided that the trial in postmeno-
pausal osteoporosis lasts C1 year, that spine BMD will be
the primary end point, and that the comparator is an
approved and established treatment for GIOP. Bridging
studies are not considered to be adequate or appropriate in
premenopausal women.
Due to uncertainties regarding the exact effect of a
specific therapy on facture rates in men and the double
BMD-based extrapolation (from postmenopausal women to
men without GIOP, then to men with GIOP), three-armed
studies of new chemical entities in men with primary
osteoporosis vs. new chemical entities in men with GIOP
versus an active comparator in GIOP are recommended.
Osteoporosis Treatment in GIOP
Although GIOP and postmenopausal osteoporosis are
pathophysiologically different, approved treatments are
similar in both groups of patients, with some geographical
variations. For instance, vitamin D metabolites and analogs
are used in GIOP, but neither 1a-hydroxyvitamin D3
(alfacalcidol) nor 1,25-dihydroxyvitamin D3 (calcitriol) is
approved for this indication in Europe or North America
[28, 51]. There is no convincing evidence that GIOP and
postmenopausal osteoporosis respond differently to current
treatments. However, some are restricted to the indication
of postmenopausal osteoporosis [selective estrogen recep-
tor modulators (SERMs), tibolone, calcitonin, and stron-
tium ranelate in Europe].
Treatment of GIOP in Different Population Subgroups
The evidence base in GIOP is limited, and information on
glucocorticoid response and safety is incomplete for some
subpopulations, especially premenopausal women, pediat-
ric subjects, and older adults. To date, few fractures have
been recorded in premenopausal women enrolled in RCTs
of bisphosphonates and teriparatide (these women have
higher baseline BMD values) [52–55]. Initiation of bis-
phosphonates is recommended in premenopausal patients
on high-dose steroids with evidence of a prevalent fracture
(Appendix). The 2010 ACR guidelines recommend newer
therapies such as zoledronic acid and teriparatide, along
with alendronate and risedronate, for the treatment of GIOP
in women of childbearing potential with a prior fragility
fracture. Estrogen replacement is no longer endorsed in
these women [46]. This panel believes that bone protective
therapy may be indicated in premenopausal women and
younger men, e.g., in individuals with a history of fracture
or those receiving high glucocorticoid doses. Women of
childbearing potential should be under appropriate contra-
ception before introducing bisphosphonates at relatively
high doses because of potential deleterious effects on the
fetus.
Pediatricians tend to treat children with glucocorticoids
because of low bone mass [56]. Reported fracture rates in
children with GIOP are very similar to those seen in
postmenopausal women [57]. Age must be taken into
consideration when evaluating fracture rates as baseline
fracture risk in pediatric disease is high. Peak fracture rate
in children occurs between the ages of 8 and 15 years,
independent of the use of glucocorticoids. Conservative
measures (Appendix) may be inadequate in the pediatric
population, giving rise to fragility fractures; and the
growing skeleton may be especially vulnerable to adverse
glucocorticoid effects on bone formation. Safety concerns
have been raised about the use of bisphosphonates in
children, and their efficacy in pediatric populations remains
unclear [58].
Further studies are needed to differentiate between
population subgroups, particularly adolescents and chil-
dren, for whom there are insufficient data to provide evi-
dence-based guidelines for GIOP prevention and treatment.
In general, however, the lowest possible effective gluco-
corticoid dose should be used for a limited period. Alter-
native approaches such as calcium and vitamin D
supplementation, exercise, and balanced diet should also be
considered (Appendix) [59]. If BMD decreases, or even
remains stable in a growing individual, bisphosphonate
treatment may be recommended. Bisphosphonates should
also be considered when higher doses of glucocorticoids
are likely to be used long term or in patients with a history
of fracture [60]. Preliminary studies in children with GIOP
have suggested a benefit of bisphosphonate intervention
during periods of high bone turnover [61], but the phar-
macokinetics of alendronate in different age groups have
yet to be described in larger subsets of patients [62].
A Cochrane review of bisphosphonate treatment (including
oral alendronate, clodronate, and intravenous [iv] pamidr-
onate) in 281 children 0–18 years with GIOP concluded
that further evaluation of bisphosphonates among children
with secondary osteoporosis is justified but did not support
bisphosphonates as standard therapy [63]. These drugs
were well tolerated with short-term use (B3 years).
Calcium and Vitamin D Supplementation
Intestinal calcium absorption is decreased in GIOP, for
reasons that are not fully understood, making the pre-
scription of calcium and vitamin D supplementation a
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logical approach [64]. Vitamin D increases intestinal cal-
cium absorption and may have a role in the maintenance of
muscular strength. Two meta-analyses demonstrated a
clinically and statistically significant prevention of bone
loss at the lumbar spine and forearm with vitamin D and
calcium in glucocorticoid-treated patients, with vitamin D
plus calcium being superior to calcium alone or no therapy
in GIOP management. Prophylactic treatment with vitamin
D plus calcium can therefore be recommended as a mini-
mum preventive strategy for GIOP in patients receiving
long-term glucocorticoids (Appendix) [65, 66].
Studies investigating the efficacy of calcium and vita-
min D supplementation in glucocorticoid-treated patients
fall into three categories: prevention studies, treatment
studies, and studies on both prevention and treatment
(Table 1). Prevention studies are those that enroll patients
within 3–4 months of starting glucocorticoid therapy and
are mostly designed to maintain BMD. Treatment studies
are those that enroll patients who have been on gluco-
corticoid therapy for [3–4 months, in whom an inter-
vention is expected to increase BMD. In general,
prevention studies used higher glucocorticoid doses and
evaluated patients at greater risk, whereas treatment
studies used lower doses; baseline T-Scores were similar
in both study types. Despite having an effect on BMD,
calcium and vitamin D supplementation as a preventive
measure in osteoporosis is much less effective than
specific antiosteoporotic treatments, regardless of the
subpopulation under study (postmenopausal and pre-
menopausal women, or men) [52–55].
Some studies have shown that bone loss can be attenu-
ated by using more polar vitamin D derivatives. Supple-
mentation with calcium and active vitamin D metabolites
(alfacalcidol or calcitriol) blunts the decline in lumbar
spine and femoral neck BMD in patients on glucocorticoid
therapy compared with untreated patients [68, 69]. How-
ever, a study in patients with asthma reported ineffective
inhibition of both lumbar spine and femoral neck BMD
decreases with calcitriol supplementation [70]. To date,
only one head-to-head comparator study of vitamin D
supplementation (alfacalcidol) versus bisphosphonates
(alendronate) has been conducted. However, the study was
not double-blinded [71]. This study is discussed further in
the bisphosphonates section. In a study of 103 patients
starting long-term glucocorticoid therapy who were ran-
domized to receive calcium with or without calcitriol and/
or calcitonin supplementation for 1 year, a greater degree
of bone loss from the lumbar spine occurred in patients
treated with calcium alone than in patients treated with
calcium plus calcitriol with or without calcitonin (mean
rate of change –4.3, –0.2, and –1.3 %, respectively;
p = 0.0035). Treatment did not have a significant effect on
bone loss at the femoral neck and distal radius [68].
A meta-analysis showed that, compared with no treat-
ment or calcium alone, supplementation with active vita-
min D derivatives resulted in a higher BMD increase and
more effective reduction of vertebral fracture risk. Com-
pared with bisphosphonates, however, active vitamin D
treatment is not as potent at increasing BMD [71, 72].
Overall, the incidence of vertebral fractures in glucocorti-
coid-treated patients receiving calcium and vitamin D from
48 weeks to 2 years, according to quantitative morpho-
metric analyses, ranged from 3.7 [53] to 18.0 % [52, 54,
73, 74] and was consistently lower in patients who received
antiosteoporosis treatment (Table 1).
Bisphosphonates in the Treatment of GIOP
Bisphosphonates are the current standard of care for GIOP.
Etidronate
A 12-month, double-blind, multicenter study in 141
patients initiating glucocorticoid therapy randomized
patients to receive etidronate (400 mg/day for 14 days,
every 3 months) or placebo [67]. All patients received
calcium 500 mg/day. The demographic distribution was
characteristic of GIOP trials, with men accounting for one-
third of participants, postmenopausal women for half, and
the remaining being premenopausal women; mean age was
around 60 years. As this was a prevention study rather than
a treatment study, the primary end point was maintenance
of BMD at 1 year. Significant maintenance of lumbar spine
BMD was seen in the etidronate group compared with a
loss of BMD in the placebo group (p \ 0.05). When these
data were broken down into subgroups, the difference
between etidronate-treated and placebo-treated patients
remained statistically significant in premenopausal
(p = 0.015) and postmenopausal (p = 0.001) women, but
not in men. The difference in femoral neck BMD was not
statistically significant (Table 1) [67].
This study included a population with a high rate of
prevalent vertebral fracture (49 vs. 45 % in the placebo-
and etidronate-treated groups, respectively). A fair number
of participants had rheumatoid arthritis and were older,
which may explain higher baseline fracture prevalence
compared with other studies. Fewer new vertebral fractures
were reported in the etidronate group (8.8 %) than the
placebo group (15.4 %) (Table 1). In addition, no patients
in the etidronate group had multiple fractures compared
with 9.2 % of patients in the placebo group [67]. Etidronate
therapy reduced the proportion of postmenopausal women
with new vertebral fractures by 85 % compared with pla-
cebo (7/32 vs. 1/31, p = 0.05). Etidronate-treated post-
menopausal women also had significantly fewer vertebral
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fractures per patient (p = 0.04). No significant difference
in the rate of new vertebral fractures was observed among
male patients, and no new vertebral fractures occurred in
either group in premenopausal women.
A number of smaller studies have evaluated etidronate
in GIOP, including two other prevention trials [75, 76] and
two treatment studies [77, 78]. Overall, the prevention
studies reported BMD maintenance, whereas the treatment
studies reported increases in BMD.
Alendronate
A combined analysis of data from two double-blind RCTs
investigated the use of alendronate in the treatment of 477
men and women aged 18–80 years with GIOP [53]. Par-
ticipants were randomized to 48-week treatment with
alendronate or placebo, stratified into ‘‘prevention’’ and
‘‘treatment’’ arms according to prior glucocorticoid expo-
sure. One hundred and sixty patients entered the prevention
arm. Two treatment arms were established according to
duration of glucocorticoid therapy: 99 patients had
4–12 months of glucocorticoid therapy, and 218 were
treated for [12 months. All patients received background
calcium (800–1,000 mg/day) and vitamin D (250–500 IU/
day) supplementation. At baseline, 43 % of patients had
lumbar spine BMD within 1 standard deviation (SD) below
the peak value for sex-matched healthy young adults; 32 %
had osteoporosis, as defined by a lumbar spine T-Score\–2
SD. Loss of lumbar spine BMD was noted in the placebo
group, but this was not statistically significant compared
with alendronate-treated patients overall. Loss of femoral
neck BMD was also noted in the placebo group, whereas a
slight improvement was seen in the alendronate group
(p \ 0.01) (Table 1) [53].
When considering the prevention versus treatment
groups separately, patients in the prevention arm had a
lumbar spine BMD response in favor of alendronate that
was highest in patients on the 10-mg dose. A gain in
lumbar spine BMD from baseline to week 48 was reported
in all four subgroups (men, premenopausal and postmen-
opausal women, and estrogen-treated postmenopausal
women) [53]. At 1 year, the combined analysis showed a
38 % reduction in lumbar spine BMD in the placebo group
(not statistically significant). Few new vertebral fractures
occurred during the study, and the incidence of morpho-
metrically defined vertebral fractures in the alendronate
groups (combined 5 and 10 mg) was not significantly lower
than that in the placebo group. The majority of new ver-
tebral fractures occurred in postmenopausal women (5/134
in the alendronate groups vs. 4/53 in the placebo group,
p = 0.05) [53].
Compared with the etidronate trial discussed above [66],
patients in the alendronate study were, on average, younger
and received a lower dose of glucocorticoids. They were
also less likely to have a prevalent vertebral fracture. Other
demographic characteristics were similar between the two
studies. Both trials found no differences in male patients,
and no new vertebral fractures occurred in premenopausal
women [53]. The selected patient populations did not allow
for further comparison of fracture risk between the two
studies. A 2-year extension of the alendronate trial revealed
that the effect of 10 mg alendronate on lumbar spine BMD
plateaued after *1 year [73]. However, upon taking the
large number of dropouts into consideration, the extension
study showed a progressive decline in femoral neck BMD
and indicated that, after longer follow-up, femoral neck
BMD may decline more than spine BMD. Overall, there
were fewer patients with new vertebral fractures in the
alendronate group compared with the placebo group (0.7
vs. 6.8 %, p = 0.026). No new vertebral fractures occurred
in patients treated with any dose of alendronate during the
second year [73].
In most studies on GIOP, the increase in lumbar spine
BMD was smaller than the reported effect in postmeno-
pausal women [53, 71, 73, 79–81]; it was similar in one
study [82] and greater in another (small) study [83]. These
comparisons should, however, be interpreted with caution
as the treatment duration and the comparator arms in these
studies were not consistent with those used in the post-
menopausal osteoporosis studies.
The pooled estimate of the relative risk for vertebral
fracture for alendronate C5 mg in postmenopausal osteo-
porosis was 0.52 (95 % CI 0.43–0.65) [79], and similar
values for vertebral fracture risk in GIOP patients treated
with alendronate have been published [73, 79, 80]. In three
of the alendronate trials, the reported effect on vertebral
fracture reduction in GIOP patients was lower than that in
postmenopausal women [71, 73, 83]. Again, this compar-
ison must be interpreted with caution as none of the dif-
ferences were statistically significant. The studies were
small and underpowered, and each used different doses and
treatment durations and included patients with different
underlying diseases.
Risedronate
Two key risedronate trials (one prevention study, one
treatment study) have been carried out in the context of
GIOP (Table 1) [52, 74, 84].
The prevention study was a 1-year RCT in 228 patients
(151 women, 77 men, mean age *59 years) initiating
glucocorticoid therapy treated with risedronate (2.5 or
5.0 mg) or placebo, with maintenance of lumbar spine
BMD as a primary outcome. All patients received calcium
(500 mg/day), and vitamin D supplementation (up to
500 IU/day) was recommended for patients whose baseline
R. Rizzoli et al.: Management of GIOP 233
123
serum levels of 25-hydroxyvitamin D3 were below the
lower limit of the normal range. Mean prednisone dose was
[20 mg/day [52]. At 1 year, lumbar spine BMD was
maintained from baseline with both risedronate doses and
was significantly greater than in the placebo-treated group
(p \ 0.05). Similarly, in femoral neck BMD, maintenance
of BMD was observed with 5 mg risedronate (p \ 0.05)
and, to a lesser extent, with 2.5 mg risedronate, with a
decline seen in the placebo group. At 1 year, a trend toward
a reduced incidence of vertebral fracture was observed in
the 5 mg risedronate group compared with the placebo
group (5.7 vs. 17.3 %, p = 0.072). This trend was also
seen in men (1/19 in the 5 mg risedronate group vs. 4/17 in
the placebo group). None of the premenopausal women
sustained a vertebral fracture [52].
The treatment study was a 1-year RCT in 290 patients
(181 women, 109 men, mean age *58 years) with a mean
duration of glucocorticoid therapy at study entry of around
5 years who were randomized to receive either risedronate
(2.5 or 5 mg) or placebo, with lumbar spine BMD as a
primary outcome [74]. All patients received calcium
(1,000 mg/day) and vitamin D (400 IU/day) supplementa-
tion. Mean prednisone dose was 15 mg/day [74]. This
study differed from other GIOP trials in that it included a
sufficient number of men to demonstrate a positive effect in
reducing fracture risk. At 1 year, significantly greater mean
lumbar spine and femoral neck BMD values were reported
for the 5 mg risedronate group compared with placebo and
for the subgroups of men, premenopausal women, and
postmenopausal women. New vertebral fractures were
reported in 15 % of patients in the placebo group and in
5 % in each risedronate group. The incidence of vertebral
fracture was reduced by an estimated 70 % relative to
placebo in both risedronate groups (p = 0.125). Statistical
significance was achieved when the data of both risedro-
nate trials were combined (p = 0.042) (Table 1) [74].
The positive effect in males seen in the treatment study
was confirmed by pooling data with the prevention study
[54]. Fewer patients in the risedronate groups experienced
multiple vertebral fractures compared with placebo, and
multiple vertebral fracture risk reduction in the risedronate
5 mg group was statistically significant (p = 0.005).
Compared with placebo, a lower incidence of vertebral
fracture was observed in men (66 % reduction, p = 0.12)
and in postmenopausal women (73 % reduction, p = 0.05)
in the risedronate 5 mg group [54].
Pamidronate
The question of whether early, intermittent, iv pamidronate
administration could prevent GIOP was addressed in a
small randomized study in 27 corticosteroid-naive patients
who commenced long-term corticosteroid therapy at a
daily dose of C10 mg prednisolone. Patients were ran-
domly allocated to receive either pamidronate (induction
infusion 90 mg iv followed by 30 mg iv every 3 months)
or calcium (800 mg/day) for as long as glucocorticoid
therapy was continued. At 1 year, the 14 patients in the
pamidronate group showed a significant increase in lumbar
spine BMD (3.6 %) and femoral neck BMD (2.2 %). In the
13 patients randomized to calcium, a significant BMD
reduction of –5.3 % was observed at both the lumbar spine
and femoral neck [85]. A second study from the same
authors, with a similar design, confirmed that BMD loss
was greater in the calcium-only group. No new vertebral
fractures occurred during the 1-year study [86].
Comparator Studies
Zoledronic Acid Versus Risedronate
The HORIZON study was a 1-year multinational, multi-
center, randomised, double-blind, double-dummy, strati-
fied, and active-controlled clinical trial in 265 men and 568
women (373 postmenopausal, 195 premenopausal). The
aim was to determine whether a single iv infusion of
zoledronic acid (5 mg) was noninferior to oral risedronate
treatment (5 mg/day) in the prevention and treatment of
GIOP. Randomization was stratified by subpopulation
(prevention/treatment) and by gender. All patients received
background calcium (1,000 mg/day) and vitamin D
(400–1,200 IU/day) supplementation [87].
Zoledronic acid was more effective than risedronate at
increasing lumbar spine BMD and total-hip BMD from
baseline levels at 12 months in both the treatment and the
prevention groups (p \ 0.0001 and p \ 0.01, respectively).
Results by treatment versus prevention subpopulations
showed that increased lumbar spine BMD was favored by
zoledronic acid in the treatment arm, whereas the preven-
tion subpopulation showed maintenance of baseline BMD
levels in the risedronate group [87].
No difference in the frequency of new vertebral frac-
tures between treatment groups was observed. When the
treatment and the prevention subgroups were combined,
the frequency of new vertebral fractures was very low (five
in the zoledronic acid group, three in the risedronate group)
[87].
Alendronate Versus Alfacalcidol
The STOP study was a 18-month, randomized, double-
dummy, double-blind clinical trial in 201 patients with a
rheumatic disease who were starting a 6-month course
of glucocorticoids (prednisone equivalent C7.5 mg/day).
Patients were randomized to receive either alendronate
10 mg/day or alfacalcidol 1 lg/day. If indicated, patients
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received calcium 500 mg/day and/or vitamin D3 400 IU/
day [71].
Greater change in lumbar spine BMD from baseline
levels was seen in the alendronate group versus the alfa-
calcidol group (4 % magnitude of difference, 95 % CI
2.4–5.5; p \ 0.001). Similar findings were reported for
total-hip and femoral neck BMD. There were fewer frac-
tures in the alendronate group compared with the alfacal-
cidol group, but the difference was not statistically
significant. The hazard ratio (HR) for nonvertebral fracture
in the alendronate group compared with the alfacalcidol
group was 0.7 (95 % CI 0.1–4.0). Three patients in the
alendronate group had a new vertebral deformity compared
with eight patients in the alfacalcidol group, of whom three
had symptomatic vertebral fractures (HR = 0.4, 95 % CI
0.1–1.4) [71].
Ibandronate Versus Alfacalcidol
The comparative efficacy and safety of ibandronate (2 mg
iv every 3 months) with alfacalcidol (oral 1 lg/day) was
investigated in a 3-year prospective cohort study in 115
patients with GIOP (lumbar spine BMD T-Score B–2.5).
All patients received calcium supplementation (500 mg/
day) [88].
After 3 years, greater increases from baseline in mean
BMD were reported at the lumbar spine (13.3 vs. 2.6 %,
p \ 0.001) and, to a lesser extent, in the femoral neck (5.2
vs. 1.9 %, p \ 0.001) with ibandronate versus alfacalcidol.
Vertebral fracture risk was also reduced (8.6 vs. 22.8 %,
respectively; p = 0.043, corresponding to a 62 % reduc-
tion in vertebral fracture risk with ibandronate), although
the study was not powered to show a difference between
the groups with respect to fracture incidence. Fewer non-
vertebral fractures occurred with ibandronate compared to
active vitamin D treatment (not significant). Patients trea-
ted with ibandronate injections also experienced less back
pain (p \ 0.001) and less loss of height (p = 0.001) than
patients receiving oral alfacalcidol [88].
Response to Bisphosphonate Treatment
The rationale for assessing whether treatment response in
GIOP patients is the same as in non-GIOP patient popu-
lations lies in the fact that GIOP patients have a very high
frequency of underlying conditions. Because of the high
prevalence of comorbidities in GIOP patients that may
confound the overall treatment response, there is a possi-
bility that a number of GIOP patients are ‘‘inadequate
responders’’ to antiosteoporotic treatment [73].
A review of antifracture efficacy in GIOP performed in
the context of a health technology–assessment exercise in
the United Kingdom concluded that the point estimate for
reduction of vertebral fracture was identical to that of
postmenopausal osteoporosis, despite the smaller numbers
of GIOP patients involved [4]. This suggests that there is
no difference in treatment response between GIOP and
postmenopausal osteoporosis.
Safety of Long-Term Bisphosphonate Use
Bisphosphonates are the most common antiosteoporotic
agents used in the treatment of GIOP. Because all trials
conducted on GIOP to date have been of limited duration,
it is not yet possible to address whether prolonged bis-
phosphonate treatments of GIOP and of postmenopausal
osteoporosis [89] are associated with similar safety issues.
Teriparatide in the Treatment of GIOP
One way to counter reduced bone formation in GIOP is
with the use of teriparatide, a recombinant form of PTH
that stimulates osteoblast activity and inhibits osteoblast
apoptosis. In general, teriparatide is reserved for more
severe GIOP and osteoporosis. High cost and the need for
daily subcutaneous injections have relegated teriparatide to
second-line therapy or for use in patients with severe dis-
ease in many countries.
Teriparatide Versus Alendronate
To date, the largest teriparatide study in GIOP is a ran-
domized, double-blind, double-dummy, active comparator-
controlled study with alendronate with a 18-month
outcome and 3-year follow-up [90–92]. Each group con-
tained 214 patients, mostly women (69 % in the alendronate
group, 72 % in the teriparatide group), with an average age
of 57 and 56 years, respectively. At study entry, average
duration of glucocorticoid therapy was *2 years with a
mean dose of 7.5–7.8 mg/day. Around 45 % of patients
were on [10 mg/day. Prior nonvertebral fracture was
recorded in 42–44 % of patients; 25–30 % had a prevalent
vertebral fracture [92].
Teriparatide displayed a clear benefit in lumbar spine and
femoral neck BMD at 12, 24, and 36 months compared with
alendronate. Lumbar spine BMD data showed significant
between-group differences as early as 6 months in favor of
teriparatide and continued significant differences between
groups at 6–18 months and at end point. The absolute incre-
ment in BMD was similar to that seen in postmenopausal
osteoporosis studies [93]. At 12 months, changes in total-hip
BMD were observed in favor of teriparatide (p = 0.01). This
remained significant at 18 months (3.8 ± 0.6 % in the teri-
paratide group, 2.4 ± 0.6 % in the alendronate group), when
the between-group difference was 1.4 % (95 % CI 0.4–2.4).
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Within-group BMD changes from baseline at the lumbar spine
and total hip were significant at all time points (p \ 0.001).
Changes from baseline in biochemical markers of bone for-
mation (P1NP) and bone resorption [C-terminal telopeptide of
type 1 collagen (CTX)] were significantly greater in the teri-
paratide group compared with the alendronate group [92].
Importantly, radiographic vertebral fracture rates at
36 months were lower with teriparatide compared to
alendronate (1.7 vs. 7.7 %, p = 0.007) (Table 1). No
clinical vertebral fractures were observed in the teriparatide
group compared with four in the alendronate group
(p = 0.037). There was no significant difference between
the groups with respect to nonvertebral fracture rate (about
7 % in each group). Overall, adverse effects were similar
between the groups. Although they occurred at a low fre-
quency, nausea, dyspnea, insomnia, viral infections, ele-
vated blood calcium, and symptomatic hypercalcemia were
more frequent in the teriparatide-treated patients [92].
In a subanalysis, results by population subgroup were
stratified according to menopausal status and gender. At
baseline, 8–12 % of the 67 premenopausal women had a
prevalent vertebral fracture compared with 32–39 % of the
277 postmenopausal women and 22–25 % of the 83 men.
At 18 months, mean percent increases from baseline in
lumbar spine BMD were greater in the teriparatide versus
alendronate group in all subpopulations. The subanalysis
concluded that teriparatide increased lumbar spine BMD to
a greater extent than alendronate in all three GIOP sub-
populations [55]. Based on these findings and the known
pathophysiology of GIOP, teriparatide might be considered
as a therapeutic strategy for patients at high risk of fracture.
Teriparatide Versus Estrogen
The effects of teriparatide and hormone replacement ther-
apy on GIOP were investigated in 51 postmenopausal
women randomized to receive either teriparatide ? estro-
gen (n = 28) or estrogen alone (n = 23). All patients
received background calcium (1,500 mg/day) and vitamin
D3 (800 IU/day) supplementation. In the teriparatide arm,
an increase in lumbar spine BMD of about 12 % was
reported compared with estrogen (p \ 0.001), along with a
very rapid increase in bone formation and resorption
markers (osteocalcin and deoxypyridinoline cross-links,
respectively). The increase in resorption markers was
somewhat delayed compared with formation markers [94].
Follow-Up
Most available data indicate that in individuals taking con-
tinuous oral glucocorticoids, bone loss and fracture risk
increase with the dose and duration of therapy [11]. Based on
expert opinion, regular BMD measurements (once a year or
every 2 years) may be indicated in patients receiving high
doses of glucocorticoids (Appendix). Furthermore, treatment
may be revised if BMD decreases or if patients experience one
or more fracture during therapy. In addition, data on markers
of bone turnover in monitoring GIOP treatments are limited.
Fracture risk declines after cessation of glucocorticoid ther-
apy; as such, bone protective therapy may be simultaneously
withdrawn. After treatment is stopped, risk assessment at the
end of treatment is generally made on the basis of age, BMD,
and fracture history [51].
Expert consensus recommends that bisphosphonate
therapy may be withdrawn in a subject on glucocorticoids
if BMD is close to normal and the patient is no longer at
increased risk of fracture or when glucocorticoids are
stopped.
Perspectives for the Treatment of GIOP
Drugs approved for the Treatment of Osteoporosis
but not GIOP
Raloxifene
Raloxifene is a nonsteroidal SERM that binds to the
estrogen receptor and reduces vertebral fracture and the
rate of bone loss in postmenopausal women [96, 97]. Other
SERMs are also available.
Few studies of raloxifene have been conducted in
postmenopausal women on glucocorticoids. In a small
randomized study, 114 long-term glucocorticoid-treated
(prednisolone 6.7 ± 5.9 mg/day) postmenopausal women
received either raloxifene (60 mg/day) or placebo, in addition
to calcium and calcitriol supplementation. Five percent of
patients had baseline vertebral fractures. At 1 year, lumbar
spine (?1.3 ± 0.4 %, p = 0.004) and hip (?1.0 ± 0.4 %,
p = 0.01) BMD increased in the raloxifene arm. In the
placebo group, a decrease in lumbar spine (–0.9 ± 0.4 %,
p = 0.045) and hip (–0.8 ± 0.3 %, p = 0.01) BMD was
observed. There were no significant changes in femoral neck
BMD. Three new fractures occurred in the placebo-treated
patients compared with none in the raloxifene arm. Bone
formation and resorption markers decreased significantly in
the raloxifene group but not in the placebo group. The authors
concluded that raloxifene displayed significant effects on
BMD and was well tolerated in postmenopausal women
receiving long-term glucocorticoid therapy [98].
Strontium Ranelate
Studies of strontium ranelate have demonstrated its anti-
fracture efficacy in postmenopausal women at varying
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degrees of fracture risk [99, 100]. Apart from an animal
study, there are no published data on the effect of strontium
ranelate in GIOP. The effects of alendronate and strontium
ranelate administration on bone were investigated in glu-
cocorticoid-treated rats. After 9 weeks of treatment with
methylprednisolone (5.0 mg/kg/day, 5 days/week), stron-
tium ranelate (900 mg/kg/day) was found to be superior to
alendronate (1.0 mg/kg/day) in terms of increased BMD at
the femoral neck and lumbar spine and in terms of histo-
morphometric parameters related to bone formation [101].
Strontium ranelate may therefore become a potential
treatment in GIOP.
The RANKL/RANK/OPG Pathway: Denosumab
The cytokine RANKL is essential for osteoclast differen-
tiation and activation [102]. OPG is an endogenous inhib-
itor of RANKL that acts as a decoy receptor [103]. Based
on the role of the RANKL/RANK/OPG system in con-
trolling bone resorption, a human monoclonal antibody
against RANKL (denosumab) was developed and has been
shown to exert beneficial effects in women with post-
menopausal osteoporosis [104].
Glucocorticoids affect expression of both RANKL and
OPG (Fig. 1) [105–107]. A recent study showed that OPG
prevented prednisolone-induced osteocyte apoptosis in
mice and that RANKL inhibition with OPG attenuates the
increased rate of glucocorticoid-induced osteocyte apop-
tosis [108]. In an earlier study, it was shown that deterio-
ration of bone strength in prednisolone-treated human
RANKL knock-in mice was prevented by denosumab.
Denosumab treatment conferred a reduction in bone turn-
over and an increase in BMD at the femur and lumbar spine
compared with placebo [109]. Together, these preclinical
data add a potentially new dimension to the mode of action
of denosumab in GIOP. Indeed, two recent reports
described osteocytes as a major source of RANKL, perhaps
more important than osteoblasts themselves [110, 111].
However, the clinical relevance of these findings remains
to be determined.
Only one study has investigated the effect of denosu-
mab in glucocorticoid-treated rheumatoid arthritis patients
participating in a phase II clinical trial [112]. In addition
to methotrexate, 218 patients were allocated to treatment
with denosumab 60 mg, denosumab 180 mg, or placebo
by subcutaneous injection at baseline and at 6 months. In
a post hoc analysis, denosumab increased lumbar spine
and hip BMD compared with placebo and reduced bio-
chemical markers of bone turnover, regardless of con-
comitant use of glucocorticoids [113]. Denosumab
therefore is potentially another effective agent in the
treatment of GIOP.
Other Molecules on the Horizon: Future Directions
in GIOP Treatment
There is evidence that glucocorticoids increase the levels of
cathepsin K, a cysteine protease expressed in osteoclasts
that degrades type 1 collagen, the principal bone matrix
protein [114, 115]. Cathepsin K inhibition with agents such
as odonacatib is therefore an attractive approach to reduce
bone resorption in GIOP because of maintained bone
formation.
Genetic studies unraveling the pivotal role of the Wnt
signaling pathway in bone metabolism have led to the
development of strategies targeting this pathway to
increase bone formation. As discussed above, this key
bone-anabolic pathway is negatively regulated by Dkk-1
and sclerostin, and expression of these Wnt inhibitors is
upregulated by glucocorticoids [36, 37]. Interestingly,
inhibition of Dkk-1 appears to reverse the glucocorticoid-
induced suppression of osteoblast differentiation. An anti-
body to sclerostin was shown to enhance bone strength in
mice treated with dexamethasone [116]. Thus, blocking
these Wnt inhibitors may result in a specific effect in
GIOP. So far, all data are from animal studies, and this
therapeutic approach has not been applied in clinical
practice. However, there are caveats associated with
blocking Wnt inhibitors. During prednisone treatment of a
patient with impaired sclerostin production, a decrease in
bone resorption was observed [117]. Therefore, because
glucocorticoids confer multiple effects that play a role in
GIOP, targeting the Wnt signaling pathway for therapeutic
purposes may be more complicated than initially thought.
Finally, another approach that may result in novel
treatment perspectives for GIOP is the development of
selective glucocorticoid receptor modulators. A glucocor-
ticoid receptor–modulating compound has been found to
have specific anti-inflammatory efficacy without affecting
osteoblast function, but this strategy remains in early
development and has so far not resulted in any clinical
investigation [118, 119].
Conclusions
Glucocorticoids are widely prescribed to suppress a variety
of diseases but are associated with well-established dele-
terious effects on bone, leading to GIOP. Both inhaled and
intermittent glucocorticoids appear to be safer than con-
tinuous oral use with respect to vertebral fracture risk,
though both options are also associated with possible del-
eterious effects on bone. There are very little data on
fracture risk in patients who receive intermittent pulse
glucocorticoids, and current guideline recommendations do
not address this treatment modality. Appropriate treatment
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of patients receiving or initiating long-term glucocorticoid
therapy is imperative in order to maintain bone health and
prevent fractures.
The pathophysiology of GIOP is not interchangeable
with that of postmenopausal osteoporosis. However, the
same treatments are used in both populations, and available
evidence suggests that GIOP does not significantly differ
from postmenopausal osteoporosis in terms of response to
therapy. Thus, despite differences in pathophysiology,
treatment response might be the same in GIOP as in
postmenopausal osteoporosis, although this needs to be
confirmed in additional analyses. Lower treatment inter-
vention thresholds have been proposed in GIOP patients.
Prior fracture is generally accepted as a treatment criterion;
age, glucocorticoid dose and treatment duration, as well as
childbearing potential should also be considered. One main
issue is that the evidence on antifracture efficacy is still
limited, as are data on markers of bone turnover in moni-
toring GIOP treatments. At the onset of glucocorticoid
therapy, it is recommended that antiosteoporotic treatment
should be initiated in individuals at increased risk of
fracture (postmenopausal women and older men with a
history of fracture, older adults aged C70 years, or post-
menopausal women and men aged C50 years on high
doses of glucocorticoids) [47]. Bone protective therapy
may also be considered in younger individuals (premeno-
pausal women and younger men), again in the event of a
previous fracture history or in those receiving high-dose
glucocorticoids.
The investigation of subpopulations of GIOP patients is
an interesting point as data in older adult, pediatric, and
premenopausal patients treated with glucocorticoids are
currently insufficient. There may be some value in per-
forming a meta-analysis of all data from premenopausal
women across all studies as there might be a specific
treatment benefit in the premenopausal population com-
pared with postmenopausal women.
Vitamin D and calcium have a role in GIOP and should, in
general, be routinely administered as supplementary therapy
in GIOP studies. As a general measure in the management of
GIOP, recommending a healthy lifestyle may be useful in
reducing the adverse effects of glucocorticoids on bone,
although there is no direct evidence that such measures
reduce fracture risk. Good nutrition, physical activity, and
avoidance of tobacco use and alcohol abuse are recom-
mended (level-C evidence in patients exposed to glucocor-
ticoids for longer than 3 months) [46, 51]. Additional
recommended measures in the management of glucocorti-
coid-treated patients include glucocorticoid-sparing therapy
and use of alternative formulations or administration routes.
As a preventive measure, even if calcium and vitamin D do
have a beneficial effect on BMD, it is much lower compared
with added antiosteoporotic treatment—in some cases
regardless of the subpopulation under study (postmeno-
pausal and premenopausal women or men). Moreover, even
if BMD is maintained with calcium and vitamin D alone,
their effect on fracture is conjectural. Calcium and vitamin D
supplementation may be used alone in very-low-risk cases
(e.g., therapy with B7.5 mg prednisolone equivalent per day
for\3 months in premenopausal women or in patients with
high bone mass). Of note, the threshold of B7.5 mg equiv-
alent prednisolone may be considered on the border of a high
dose (FRAX nomenclature) and associated with a degree of
risk. In recent years, there has been a tendency to revise down
these thresholds, although glucocorticoid treatment duration
also needs to be taken into account.
Data show that vitamin D derivatives are more active
than vitamin D, but no head-to-head comparative studies
have been conducted. A trend toward improved BMD and
lower fracture rates has been observed with active metab-
olites, but this is counterbalanced by the risk of hypercal-
cemia and hypercalciuria with the use of more polar
vitamin D derivatives [68]. There are no data on whether
glucocorticoid-treated patients have lower vitamin D levels
compared with the general population. Glucocorticoid-
responsive elements have been identified in the vitamin D
receptor and other genes that control vitamin D synthesis,
so it is conceivable that glucocorticoids could influence the
metabolism of vitamin D [120].
Absence of evidence of fracture risk reduction in GIOP
should not be interpreted to mean that antiosteoporotic
drugs are ineffective. Available GIOP studies are often
short term and do not include very large numbers of par-
ticipants. There is good evidence for a number of drugs in
the treatment of postmenopausal osteoporosis, with respect
to the effect on spinal and proximal femur BMD and on
reductions in vertebral fracture.
Bisphosphonates appear to be of benefit in individuals
with GIOP. These agents are the most commonly used in
GIOP treatment and generally well tolerated, but they are
associated with adverse reactions [95]. Regular BMD
measurements may be indicated in patients receiving high
doses of glucocorticoids, and treatment may be adjusted in
the event of a BMD decrease or multiple fractures during
therapy. Fracture risk declines after cessation of gluco-
corticoid therapy. As such, bone protective therapy may be
simultaneously withdrawn, but there is no consensus on the
recommended timing for withdrawal.
A major issue in GIOP is reduced bone formation. Bone
formation is stimulated by teriparatide therapy, suggesting
that teriparatide may be one of the most effective available
therapies in GIOP. Teriparatide has been shown to have
superior BMD efficacy compared with alendronate, but
side effects are more commonly observed with teriparatide.
In general, teriparatide is reserved for more severe GIOP
and osteoporosis.
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In addition to bisphosphonates and teriparatide, several
drugs currently approved in some countries for the treat-
ment of postmenopausal osteoporosis, such as raloxifene,
strontium ranelate, and denosumab, may become an option
in GIOP. Other potential future treatments of GIOP include
cathepsin K inhibitors, inhibitors of components of the Wnt
signaling pathway, and selective glucocorticoid receptor
modulators.
In summary, the available evidence shows that many of
the therapies effective in postmenopausal osteoporosis are
also effective in the treatment of GIOP. Fracture end-point
studies and additional studies investigating specific sub-
populations are needed to strengthen this conclusion.
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Appendix: General Measures and Recommendations
in GIOP Management
General measures
Glucocorticoid-sparing therapy: reduce glucocorticoid dose
whenever possible
Consider alternative route of glucocorticoid administration
Advise good nutrition, especially with calcium and vitamin D
Recommend regular weight-bearing exercise
Avoid tobacco use and alcohol abuse
Assess falls risk and advise accordingly
Monitoring recommendations during glucocorticoid therapy
Assess adherence to therapy, including calcium and vitamin D
If suspect vertebral fracture, assess by X-ray or DXA-based vertebral
fracture assessment
Measure height annually and BMD at appropriate intervals
(especially in patients on high glucocorticoid dose)
Measure serum P1NP after 3 months of teriparatide therapy
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